Calium

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calium

Property Description
Active ingredient Calcium Polystyrene Sulfonate (CPS)
Form Oral Powder (mixed into suspension)
Pharmacological class Potassium Binder / Electrolyte Modulator
Common use Lowering high blood potassium (Hyperkalemia)
Origin Synthetic Ion-Exchange Resin

Calium refers to a prescription medication whose active ingredient is the INN Calcium Polystyrene Sulfonate (CPS), which is clinically recognized for its ability to correct severe electrolyte imbalances. It is classified as a Potassium Binder and Electrolyte Modulator. This drug is primarily intended to manage hyperkalemia, a life-threatening condition caused by excessively high levels of potassium in the blood, often occurring in patients with chronic kidney disease.


What Type of Medicine is Calium?

Calium operates as a synthetic ion-exchange resin that functions exclusively within the gastrointestinal tract; it is not absorbed into the bloodstream. This medication works by chemically exchanging its calcium component for potassium ions in the gut. This ion-exchange mechanism draws potassium out of the body, and the medicine is used to treat high levels of potassium in the blood.

Calcium Polystyrene Sulfonate is a single-ingredient therapy. It is specifically designed to perform a distinct role: maintaining the critical electrolyte balance necessary for proper cardiovascular and neurological function. The medication's primary function is the removal of excess potassium.


What Form Does Calium Take?

Calium is typically provided as a fine powder, distinguishing it from many medications that come as tablets or capsules. This powder must be dissolved or suspended in water for administration, either orally or, less commonly, rectally. This specialized form is crucial because it ensures the active ingredient is spread throughout the intestines, maximizing the surface area available to bind potassium and facilitate its removal from the body.

What side effects are possible with Calium?

Possible Side Effects and Safety Information

The safety characteristics of Calium (Calcium Polystyrene Sulfonate) are documented based on its activity within the gastrointestinal tract and its impact on systemic electrolyte levels. Officially classified adverse reactions are grouped primarily into Metabolism and Nutrition Disorders and Gastrointestinal Disorders.

Electrolyte shifts are common, including hypokalaemia (low blood potassium), hypercalcaemia (high blood calcium), and hypomagnesaemia (low blood magnesium). Common gastrointestinal effects involve nausea, vomiting, and constipation.

Serious adverse reactions, which have been reported and can be fatal, relate to the integrity of the digestive tract. These include intestinal necrosis, intestinal perforation, and gastrointestinal stenosis. The risk of these severe events is substantially increased when the medication is co-administered with sorbitol, a combination that is officially not recommended.

Classification Examples of Reactions
Common Hypokalaemia, Nausea, Constipation, Hypercalcaemia
Rare Intestinal Necrosis, Fecal Impaction, Gastrointestinal Concretions

Specific safety constraints are noted for vulnerable patient groups. Oral administration is strictly contraindicated in neonates. Particular caution is required when using the medication rectally in neonates and children due to the documented risk of colonic necrosis and faecal impaction. Furthermore, the accidental inhalation or aspiration of the powder particles can lead to very rare, but serious, bronchopulmonary complications such as acute bronchitis or bronchopneumonia, requiring careful positioning during administration.

Overdose and Emergency Response

The official regulatory profile for Calium (Calcium Polystyrene Sulfonate) overdose is defined by the risk of excessive ion exchange within the body, which leads to profound electrolyte derangement. Documented overdose presentations primarily involve the development of severe hypokalemia (abnormally low serum potassium) and severe hypercalcemia (abnormally high serum calcium levels), along with gastrointestinal effects such as nausea and vomiting.

The most serious outcomes described are related to this imbalance, particularly life-threatening ECG changes and potential ventricular arrhythmias linked to hypokalemia. Furthermore, the physical nature of the resin carries an officially noted acute gastrointestinal complication risk, including the potential for intestinal obstruction or necrosis.

Due to these potential severe effects, the regulatory mandate is absolute: seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if signs of severe cardiac distress or profound electrolyte imbalance are present.

Management of Calium overdose focuses on symptomatic and supportive treatment. As stated in official documentation, no specific antidote is known. Intervention requires close clinical observation, which often includes continuous ECG monitoring and repeated laboratory measurements to correct the resulting potassium and calcium imbalances. Patients with pre-existing bowel disease or those in the immediate post-operative period carry a specific, documented increased risk for severe gastrointestinal complications in an overdose setting.

Therapeutic Uses of Calium

What Calium Treats: Main Uses and Benefits

Calium (Calcium Polystyrene Sulfonate, CPS) is used for managing symptoms related to systemic imbalance, especially in conditions involving high blood potassium levels (hyperkalemia). This therapeutic support is often applied in situations where patients experience functional stress due to compromised kidney function, such as those with Chronic Kidney Disease (CKD) or Acute Kidney Injury (AKI). The medication is commonly used to help with hyperkalemia, as high potassium levels are linked to symptoms that may create noticeable functional strain on the heart, potentially leading to irregular heart rhythms.


Quick Fact: Relief for Hyperkalemia

  • Target: High blood potassium levels (hyperkalemia)
  • Benefit: Supports cardiac electrical stability; assists with maintaining functional stability

This management may assist in mitigating the potential for cardiac risk, which is often associated with high potassium. Calium is applied across therapeutic domains where additional symptomatic support is needed due to heightened physiological activity. Specifically, it is relevant in clinical scenarios used for managing hyperkalemia associated with Chronic Kidney Disease, Acute Kidney Injury, and other forms of renal failure.

“This treatment is commonly used to help achieve stable potassium levels over the long term, preventing acute fluctuations.”

Calium is commonly used across conditions characterized by periods of heightened symptoms as a maintenance therapy. It is applied when supportive symptom management is appropriate, and this ongoing therapeutic assistance supports patients during periods where symptoms are more noticeable, which are related to the underlying imbalance, assists with maintaining functional stability, and may assist patients in maintaining their treatment plan for other conditions.

Eligibility and Restrictions for Use

Official Eligibility Profile for Calium

Calium (Calcium Polystyrene Sulfonate) is designated for use in adults, including the elderly, to manage hyperkalemia. However, regulatory documents establish strict contraindications and restrictions based on physiological status and age.

Category Official Regulatory Status
Populations Contraindicated Patients with serum potassium levels below 5 mmol/L (hypokalemia); conditions associated with hypercalcemia (e.g., multiple myeloma, sarcoidosis); history of hypersensitivity to the resin; and obstructive bowel disease.
Age-Related Rules Oral use is contraindicated in neonates. Rectal administration requires particular care in all children and is contraindicated in neonates with reduced gut motility.
Specific Restrictions Not recommended for patients with compromised gastrointestinal motility (e.g., immediate post-surgery) or in those who develop clinically significant constipation. The concomitant use of Sorbitol is not recommended due to risk of serious gastrointestinal events.
Pregnancy/Lactation Not advised unless the potential benefits outweigh any potential risks, due to insufficient human safety data.

Eligibility is defined by excluding patients with these specific metabolic, gastrointestinal, or age-related limitations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions involving Calium (Calcium Polystyrene Sulfonate) are primarily governed by its non-systemic binding property in the gastrointestinal tract and its pharmacodynamic effect on electrolytes, as documented in regulatory information.


Documented Combination Restrictions

Category Interacting Substance Regulatory Restriction
Prohibited Sorbitol Use is formally avoided/contraindicated due to risk of serious gastrointestinal injury.
Avoided Magnesium-containing laxatives Co-administration is avoided due to the risk of metabolic alkalosis.
Food Restriction Potassium-rich liquids (e.g., certain juices) Must not be mixed with the powder, as this reduces the drug's effectiveness.

Exposure and Timing Constraints

Calium may decrease the absorption of many other orally administered medications (such as Lithium and Levothyroxine) by binding to them in the gut. To mitigate this exposure reduction, regulatory documents require the administration of Calium to be separated from all other oral medicines by at least 3 hours. This separation window is extended to at least 6 hours for patients with conditions causing delayed gastric emptying.

Pharmacodynamic Risk

The profile also notes a significant pharmacodynamic interaction with Digitalis-like drugs (Cardiac Glycosides). If Calium-induced changes in electrolytes, specifically hypokalaemia (low potassium) or hypercalcaemia (high calcium), occur, these shifts can exaggerate the cardiotoxicity of the co-administered drug, as formally stated in prescribing information.

Mechanism of Action

How Calium Works: Mechanism of Action


The action of Calium's active ingredient, Calcium Polystyrene Sulfonate, is defined by a chemical ion-exchange reaction that occurs exclusively in the gastrointestinal tract. This mechanism is peripheral and non-absorbed, acting as a potassium sequestrant solely within the gut lumen. The process relies on the resin's sulfonic acid groups to preferentially bind potassium ions (K^+) present in the colon, while simultaneously releasing its own calcium ions (Ca^2+). This physical sequestration of K^+ prevents its absorption into the bloodstream, resulting in a net reduction of intestinal potassium entry.

The physiological consequence of the sequestration cascade is an alteration in systemic potassium concentration. The sustained removal of potassium ions via the feces reduces the concentration gradient available for absorption, contributing to a reduction in the total body potassium load. This predictable, gradual adjustment of the electrolyte balance leads directly to a lowering of serum potassium concentration and the modulation of electrochemical gradients.

However, the mechanism's efficacy is dependent on the duration of contact between the resin and the ions, dictating a delayed and gradual physiological change. It also faces inherent cation competition from other ions like magnesium in the gut, which results in an incomplete exchange ratio for potassium.

Dosage and Administration Information

Calium (Calcium Polystyrene Sulfonate) is supplied as a fine powder and is administered via the oral route, as a prepared suspension, or the rectal route, as a retention enema. The specific dose and duration are determined by regular electrolyte monitoring.

Standard Administration and Preparation

For oral administration, the usual adult regimen is 15 g of the resin taken in divided doses, typically three or four times daily. The powder must be suspended in a small volume of water or a sweetened liquid, ensuring the mixture is prepared immediately before use. Administration guidelines include a caution against mixing the powder with fruit juices because of their naturally high potassium content.

A critical requirement for proper oral use is the separation of administration timing. The drug must be taken at least three hours before or three hours after any other oral medication to prevent binding that could reduce the effectiveness of the other medicine. This separation time is extended to six hours for patients who have conditions such as gastroparesis.

Dosing for Specific Populations

For children and infants, a reduced dose based on body weight is used, starting with 1 g per kilogram daily in divided doses, which is often halved for ongoing maintenance. A key constraint for the youngest patients is that oral administration is contraindicated in neonates. If the rectal route is used, the adult dose involves suspending 30 g of resin in an aqueous vehicle, followed by mandatory colon irrigation to ensure complete removal of the substance after the procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calium


Evidence for Use in Research Exploring Hyperkalemia

Research for Calium (Calcium Polystyrene Sulfonate) was evaluated in research exploring the use of Calium in high blood potassium levels, a condition known as hyperkalemia. These studies explored the effect of the medicine in adult populations and primarily focused on outcomes monitoring physiological strain or stress related to high potassium. The evidence base includes short-term Randomized Controlled Trials (RCTs) and longer-term observational studies.

The key measure studied in these trials was the measurement of changes in Serum Potassium Levels—a biomarker shift measured in the blood. Studies have reported measurements of decreases in serum potassium concentrations following Calium administration. Some trials described patterns where the use of the medicine was observed to be associated with achieving and maintaining measured potassium levels within specific target ranges set by clinicians.


Study Focus: Chronic Kidney Disease and Dialysis Patients

A significant portion of the research on Calium was evaluated in patients who have underlying kidney conditions, which are often associated with hyperkalemia. This includes individuals with Chronic Kidney Disease (CKD) and patients undergoing maintenance hemodialysis. For CKD patients, studies examined the use of Calium as a maintenance therapy applied in research contexts involving fluctuating or unstable symptoms of high potassium.

In the population undergoing maintenance hemodialysis, research specifically monitored how the medicine affected potassium levels during the days between dialysis sessions. Findings indicate that in some cohorts, Calium was associated with managing potassium levels during these inter-dialytic periods. Furthermore, studies monitored other electrolyte levels and reported measurements of serum calcium, which was a key outcome examined in these trials.


Understanding Research Gaps and Uncertainties

Evidence quality and design parameters differ across reports, with some older reports utilizing modest sample sizes. The current evidence landscape provides context regarding the measured potassium biomarker shift, and outlines areas that remain uncertain. Long-term effects are not fully established regarding hard clinical outcomes, since the research primarily focuses on the biochemical marker (potassium levels). For specific populations, such as children or neonates, data for these groups remain limited or unavailable in regulatory reports. Researchers note that due to these limitations, the treatment must be viewed in the context of the available evidence, which does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Calium (FAQ)

Q: Can I take Calium with vitamins or supplements?

A: Regulatory information indicates that Calium has the potential to bind to other substances taken by mouth, including vitamins and supplements, which could reduce their absorption and effectiveness. For this reason, official product information includes a requirement to separate the administration of Calium from all other oral products by at least three hours.

Q: Does Calium affect birth control pills?

A: Official product information notes that Calium may bind to many orally administered medications, which could decrease their absorption in the digestive tract. To reduce the potential for this interaction, regulatory documents specify that the dose of Calium must be separated from any other oral medicine, including birth control pills, by at least three hours.

Q: Is it normal to feel tired when first starting Calium?

A: Tiredness or weakness is not listed as a common side effect in the official safety profile. However, symptoms such as weakness may be associated with shifts in electrolyte levels, such as low potassium (hypokalemia), which is a reported effect noted in the product information.

Q: Are there different strengths or versions of Calium?

A: Calium's active ingredient, Calcium Polystyrene Sulfonate, is generally supplied as a fine powder intended for preparation into a suspension. While the powder itself may be packaged in different container sizes, some suppliers in certain regions may offer the active ingredient as a pre-mixed suspension (a ready-to-use liquid mixture).

Q: Can I crush or split Calium tablets?

A: Official documents define Calium as a powder, which must be prepared into a suspension before use. It is not typically supplied as a tablet or capsule. The powder form is intended to be mixed with water or a sweetened liquid immediately prior to administration.

Q: Does Calium need to be taken with food?

A: Regulatory guidelines primarily focus on the requirement to separate Calium administration from other oral medicines and high-potassium liquids like fruit juice. While the product is generally taken with a small amount of water or syrup, some official guidelines indicate that the medication may be administered without food.

Q: Will Calium affect my ability to drive or operate machinery?

A: Regulatory documents have assessed the effects of Calium on the central nervous system and indicate that its influence on the ability to drive or use machines is generally considered minimal.

Q: Can Calium cause long-term side effects?

A: The official documents mention that serious adverse reactions, such as intestinal injury, have been reported in the medical literature, particularly when the drug is used with sorbitol. Furthermore, the available research primarily focuses on the short-term measured effect on potassium levels, and long-term effects on overall clinical outcomes are not fully established.

Q: Is Calium used for any other conditions besides the main ones listed?

A: The official product information and regulatory documents strictly indicate Calium only for the treatment of hyperkalemia (high blood potassium levels). Discussion of other uses falls outside of the approved indication.

Q: What should I do if I accidentally take more Calium than prescribed?

A: Taking more Calium than prescribed may lead to shifts in blood electrolyte levels, such as low blood potassium (hypokalemia) or high blood calcium (hypercalcemia). In cases of potential overdose, regulatory guidance describes that measures may be necessary to correct serum electrolyte levels and facilitate the removal of the active substance from the digestive tract.

Q: Does Calium show up on a standard drug test?

A: Calium is classified as a non-absorbed resin. Regulatory pharmacological information confirms that the active ingredient is not absorbed into the bloodstream. It works solely within the gastrointestinal tract and is fully excreted in the feces.

Q: What is the difference between Calium and a placebo in clinical trials?

A: Calium was studied for its measured effect on serum potassium levels. Research evidence indicates that trials reported measurements showing decreases in serum potassium concentrations following administration, while a placebo is an inactive substance used for comparative assessment.

Q: Does Calium cause weight gain?

A: Weight gain is not listed as a direct side effect in the official safety profile. However, a related formulation (Sodium Polystyrene Sulfonate) contains sodium, and its use is associated with a risk of fluid retention (edema), which may contribute to measured weight changes in some patients.

Q: Does Calium affect blood pressure?

A: Blood pressure changes are not listed as a direct side effect. However, a related formulation (Sodium Polystyrene Sulfonate) contains sodium, and the presence of high sodium is a factor that is generally considered for patients with certain vascular conditions.

Q: Is Calium available in liquid form?

A: Calium is typically supplied as a powder that must be mixed into a suspension, which is a liquid mixture, immediately before use. In some regions, however, the active ingredient may be supplied by a pharmacy as a pre-mixed oral or rectal suspension.

Q: What is the shelf life of Calium?

A: Regulatory instructions require the powder form of Calium to be stored in a tightly closed container protected from moisture to maintain its stability. The suspension prepared for administration must generally be used immediately. If the product is repackaged, official guidance states that the stability and storage time may be limited and must be defined by the pharmacist.

Q: Does Calium interact with herbal teas or natural supplements?

A: Official regulatory documents indicate a requirement to separate the administration of Calium from all other orally taken products, including natural supplements, due to the potential risk of binding and reduced absorption. Some natural products or teas may also be high in potassium and could reduce Calium’s effectiveness if taken too closely together.

How should Calium be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of Calcium-containing products to maintain stability and ensure environmental safety.

Storage Classification Requirement Summary
Temperature Control Store at controlled room temperature (15 C to 30 C) or refrigerated (2 C to 8 C), depending on the formulation. Do not freeze.
Environmental Protection Keep the product protected from moisture and light by storing in a tightly closed container. Avoid storing near incompatible substances, such as acids.
Handling Avoid the formation of dust and ensure adequate ventilation during handling. Pharmacy bulk packages are for mixing only, not direct infusion.
Disposal Dispose of the product and its container through an approved waste disposal facility. Do not release the product into the environment, including water sources or sewer systems, as this is prohibited by official regulatory instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calium found in:

A-Z Index: